{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":57,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":57,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"458495b2c95b","filters":{"venue":"Targeted Oncology"}},"results":[{"id":"W2742486699","doi":"10.1007/s11523-017-0518-1","title":"Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars","year":2017,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":171,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital","funders":"Pfizer","keywords":"Bevacizumab; Biosimilar; Medicine; Colorectal cancer; Oncology; Intensive care medicine; Internal medicine; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.06030926735329518,"gpt":0.4066597918623675,"spread":0.3463505245090723,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007954383,0.000432629,0.003116016,0.000302792,0.00009957594,0.000009956168,0.0004468397,0.001134942,0.0002242005],"category_scores_gemma":[0.0001548592,0.0002431739,0.0004101666,0.0001810067,0.001310551,0.00002741191,0.0002125662,0.0008149238,0.0000112032],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004146558,"about_ca_system_score_gemma":0.0006837382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005726122,"about_ca_topic_score_gemma":0.00143305,"domain_scores_codex":[0.9962395,0.001814013,0.0009208226,0.0005057344,0.00003289021,0.0004869903],"domain_scores_gemma":[0.9983274,0.0006273214,0.00065721,0.0003188004,0.00003759631,0.0000316527],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003999412,0.0003169263,0.00008070187,0.000518531,0.0003297064,0.00001720304,0.0001093579,3.702394e-7,0.0001441257,0.0001808351,0.0001550254,0.9977473],"study_design_scores_gemma":[0.004676242,0.0004991791,0.0003203712,0.001152174,0.0009647781,0.00006897802,0.0000390077,0.000009159635,0.0001683835,0.0003058192,0.9915407,0.0002551556],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0005877764,0.9961729,0.000001723738,0.0003976066,0.001092621,0.001152339,0.0002527379,0.00001045667,0.0003318381],"genre_scores_gemma":[0.002019324,0.9973257,0.00006265904,0.0000296674,0.00005296958,0.0003153539,0.00007190747,0.00002086662,0.0001015177],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9974921,"threshold_uncertainty_score":0.9916342,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2765084883","doi":"10.1007/s11523-017-0530-5","title":"A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PI3K/AKT/mTOR signaling in cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":95,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Plexxikon; Symphogen; Genentech; Celgene; Sanofi; Ipsen; Chugai Pharmaceutical; Sirtex Medical; Pfizer; Eli Lilly and Company","keywords":"Medicine; Irinotecan; Tolerability; Clinical endpoint; Internal medicine; KRAS; Colorectal cancer; Pharmacokinetics; Pharmacology; Phases of clinical research; Combination therapy; Endometrial cancer; Oncology; Cancer; Urology; Toxicity; Adverse effect; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.03309205630219511,"gpt":0.3685072594238245,"spread":0.3354152031216294,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005704103,0.0004023284,0.0006114789,0.00008841295,0.000472889,0.00004699292,0.001073641,0.0004025481,0.00008022862],"category_scores_gemma":[0.0007000043,0.0002358646,0.0001233162,0.0001816194,0.0006675378,0.00002229534,0.0007544854,0.0005089352,0.000003094219],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002519934,"about_ca_system_score_gemma":0.000829522,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00149458,"about_ca_topic_score_gemma":0.01378081,"domain_scores_codex":[0.9972559,0.0004058643,0.0006680146,0.0007816053,0.0002942851,0.0005943478],"domain_scores_gemma":[0.9974871,0.0001221911,0.0007138692,0.001334284,0.0002015443,0.0001409914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004414432,0.003070624,0.02407406,0.0000926082,0.000380036,0.00008367751,0.003855504,0.0009190509,0.9259074,0.00001156978,0.003397693,0.03379331],"study_design_scores_gemma":[0.04897723,0.01385704,0.03949884,0.000269006,0.0003741093,0.00007662195,0.005140101,0.001465957,0.7891095,0.00006075189,0.09980402,0.001366799],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938735,0.001774764,0.00003098721,0.0009022313,0.001670267,0.001480902,0.0001277361,0.00002048319,0.0001190915],"genre_scores_gemma":[0.9974502,0.000270208,0.0003161992,0.0003980802,0.0005963633,0.0004019366,0.00001678338,0.00006157365,0.0004886522],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1367979,"threshold_uncertainty_score":0.9618278,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2914232272","doi":"10.1007/s11523-018-00617-1","title":"Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":75,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Nausea; Proteinuria; Adverse effect; Peripheral edema; Internal medicine; Vomiting; Dosing; Pharmacodynamics; Pharmacokinetics; Gastroenterology; Pharmacology; Oncology; Kidney","retraction":null,"screen_n_in":null,"score":{"opus":0.02749436018870834,"gpt":0.3522023992081704,"spread":0.3247080390194621,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003280329,0.0002043609,0.001044852,0.0004738136,0.00002064903,0.000002474847,0.0001695846,0.0001171492,0.0004968477],"category_scores_gemma":[0.0002927868,0.0001340255,0.00004913748,0.0006969344,0.0001390086,0.00009809762,0.0001026205,0.0002623144,0.00002513924],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001361419,"about_ca_system_score_gemma":0.0003893324,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006733975,"about_ca_topic_score_gemma":0.0001517934,"domain_scores_codex":[0.9975783,0.0003760615,0.000682139,0.0004151913,0.0005757116,0.0003726283],"domain_scores_gemma":[0.9984064,0.0002816676,0.0003048797,0.0004693846,0.0003854949,0.0001522084],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.05797693,0.07480046,0.4272079,0.000948628,0.0001852897,0.0009416326,0.002443044,0.0001450304,0.4174441,0.00003804336,0.0001518935,0.01771705],"study_design_scores_gemma":[0.1348252,0.4491524,0.2423888,0.0003984224,0.0002547417,0.00003506602,0.008755454,0.0009850134,0.1623263,0.00004706735,0.0003882145,0.0004433235],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969628,0.0000813415,0.00002085544,0.00003816246,0.000072719,0.002654803,0.00001536412,0.00002302089,0.0001308989],"genre_scores_gemma":[0.996335,0.000007979113,0.003303345,0.00005203208,0.000007819531,0.00007021134,0.00006452583,0.00002974209,0.0001293134],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3743519,"threshold_uncertainty_score":0.54654,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2201788027","doi":"10.1007/s11523-015-0396-3","title":"Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":70,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Prostate; Adenocarcinoma; Prostate adenocarcinoma; Prostatic adenocarcinoma; Pathology; Lymphocyte; Castration; Prostate cancer; Oncology; Internal medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03854617420081482,"gpt":0.3205983842461482,"spread":0.2820522100453334,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003228527,0.0001826446,0.0005457874,0.0002568861,0.00005506206,0.00001129727,0.00008719926,0.0001887045,0.0002356642],"category_scores_gemma":[0.00005036666,0.0001510556,0.00007360542,0.0003625264,0.0001778414,0.0001169664,0.00003150199,0.0001198594,0.00001044896],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003066442,"about_ca_system_score_gemma":0.0005356015,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008391094,"about_ca_topic_score_gemma":0.00067351,"domain_scores_codex":[0.9984961,0.0002234464,0.0004255052,0.0003772294,0.0002596942,0.0002180479],"domain_scores_gemma":[0.9989187,0.00008256857,0.0002191457,0.0003676192,0.0001790594,0.0002329249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02709554,0.0004581049,0.01514818,0.00003795163,0.0006354932,0.0002194847,0.005891235,0.00004237299,0.9364212,0.00001213509,0.00120726,0.01283104],"study_design_scores_gemma":[0.02086211,0.01359552,0.4193936,0.0001305467,0.001815391,0.00003516165,0.007088773,0.000453006,0.5180161,0.0002449273,0.01785441,0.0005104787],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927978,0.005708605,0.0000533429,0.0002885082,0.0001648949,0.0003623397,0.0001001479,0.0000434931,0.0004809009],"genre_scores_gemma":[0.9967533,0.0002035392,0.001982813,0.0003741944,0.0001132337,0.00004248388,0.0003177086,0.00002057932,0.0001921393],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4184051,"threshold_uncertainty_score":0.6159868,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1999755104","doi":"10.1007/s11523-014-0308-y","title":"Transforming growth factor-beta and its implication in the malignancy of gliomas","year":2014,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"TGF-β signaling in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":66,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Sherbrooke","funders":"","keywords":"Glioma; Medicine; Cancer research; Malignancy; Transforming growth factor beta; Angiogenesis; Cytokine; Growth factor; Transforming growth factor; Pathology; Hepatocyte growth factor; Immunology; Internal medicine; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.02932850146755989,"gpt":0.3367804522802084,"spread":0.3074519508126485,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002871067,0.0002674868,0.0008064878,0.0001249611,0.00004111193,0.000007293,0.0004077277,0.0005483898,0.0000150457],"category_scores_gemma":[0.0001082207,0.0001933824,0.0001884505,0.0001706665,0.00007535652,0.000003064278,0.00005868645,0.0001752918,0.000005538775],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002853762,"about_ca_system_score_gemma":0.0003035796,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000009409779,"about_ca_topic_score_gemma":0.00002056381,"domain_scores_codex":[0.9983212,0.0003826739,0.0005647214,0.0003852074,0.0001008481,0.0002453398],"domain_scores_gemma":[0.9991084,0.000129926,0.0003365123,0.0003056028,0.00006817548,0.00005140011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006194322,0.0003233315,0.0001199855,0.01537738,0.0003071252,0.00001895424,0.0003671274,0.000001424129,0.04026325,0.001830471,0.0003469841,0.940982],"study_design_scores_gemma":[0.0003463441,0.0003803108,0.0001330479,0.0007059195,0.0002561795,0.00006206381,0.00001716109,0.000001310391,0.008027805,0.00006468488,0.989728,0.000277203],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.007237243,0.9914206,0.00009786119,0.00003043619,0.00007335375,0.0007031624,0.00007795995,0.000008627841,0.0003507119],"genre_scores_gemma":[0.08023856,0.9187873,0.000079385,0.00005307128,0.0001525845,0.0001856678,0.0004475782,0.00003658581,0.00001928465],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.989381,"threshold_uncertainty_score":0.7885905,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1627803359","doi":"10.1007/s11523-015-0386-5","title":"Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Genomics, phytochemicals, and oxidative stress","field":"Biochemistry, Genetics and Molecular Biology","cited_by":55,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children","funders":"","keywords":"Medicine; Cancer research; Sulforaphane; Protein kinase B; PI3K/AKT/mTOR pathway; Clonogenic assay; Apoptosis; Bladder cancer; Epithelial–mesenchymal transition; Survivin; Pharmacology; Cancer; Internal medicine; Chemistry; Metastasis; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01358908671145698,"gpt":0.2522022828085155,"spread":0.2386131960970586,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002787308,0.0001755629,0.0003568955,0.00007556977,0.00003497579,0.000005856201,0.00009770469,0.0001455981,0.000005271632],"category_scores_gemma":[0.0001805709,0.0001577991,0.00003485583,0.0001082664,0.0002865931,0.000007704944,0.00005355718,0.00009035424,5.945279e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001851189,"about_ca_system_score_gemma":0.0001207723,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006735767,"about_ca_topic_score_gemma":0.00005272898,"domain_scores_codex":[0.9989416,0.00009736388,0.0002981008,0.0003215154,0.0001194762,0.0002219148],"domain_scores_gemma":[0.9990661,0.00008548232,0.0001960929,0.0001350151,0.0003922556,0.0001250142],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0009793129,0.0002034155,0.001177519,0.00005299285,0.0001060658,0.000004138152,0.0006813885,0.0002408323,0.9958898,0.0001625107,0.00002897553,0.0004730853],"study_design_scores_gemma":[0.003652659,0.003448374,0.002570451,0.00001908751,0.00008380691,0.00003973966,0.001304042,0.0006250959,0.9868835,0.0005339225,0.0005819668,0.0002573287],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919531,0.000636985,0.006452534,0.0002498186,0.00007220932,0.0003340946,0.0001205742,0.00000814193,0.0001725953],"genre_scores_gemma":[0.9964445,0.00007894139,0.003085288,0.0001358876,0.00006005305,0.00001392951,0.0001388391,0.0000220589,0.00002050445],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009006238,"threshold_uncertainty_score":0.6434863,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2560844514","doi":"10.1007/s11523-016-0462-5","title":"Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Pfizer","keywords":"Medicine; Sunitinib; Placebo; Quality of life (healthcare); Neuroendocrine tumors; Internal medicine; Adverse effect; Oncology; Cancer; Pathology; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.08123099894244132,"gpt":0.4184935309884916,"spread":0.3372625320460503,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.000242781,0.0002293416,0.0009255885,0.0001919271,0.00005157546,0.000009729403,0.0001523359,0.00001700937,0.0001392518],"category_scores_gemma":[0.01008897,0.0001448084,0.00008260972,0.0001155717,0.0003168042,0.0002321901,0.00008344068,0.0001709093,0.000002417041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009180485,"about_ca_system_score_gemma":0.0003867919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005165967,"about_ca_topic_score_gemma":0.0002639272,"domain_scores_codex":[0.997199,0.0003299393,0.00105417,0.0005436582,0.0004588765,0.0004143645],"domain_scores_gemma":[0.9950408,0.003116392,0.0006804538,0.0004576325,0.0003714141,0.0003332761],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9668189,0.001468396,0.008230414,0.00003099017,0.0004319919,0.00110461,0.0001131648,0.000001502509,0.01302904,0.0001138661,0.0003928774,0.008264218],"study_design_scores_gemma":[0.924448,0.04185712,0.01496364,0.00006855046,0.0002022319,0.0001465806,0.0003746631,0.00007300884,0.009761002,0.0001699861,0.007690788,0.0002444968],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9924564,0.00002306635,0.00005580055,0.003845325,0.0004486249,0.001952215,0.0006419031,0.0000834261,0.0004931756],"genre_scores_gemma":[0.9968273,0.00003791597,0.001721329,0.0002740668,0.000225118,0.0002174017,0.0003797862,0.0000343618,0.0002827437],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.042371,"threshold_uncertainty_score":0.9982495,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1967370517","doi":"10.1007/s11523-014-0356-3","title":"Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy","year":2015,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Medicine; Renal cell carcinoma; Internal medicine; Neutrophilia; Lymphocytopenia; Nephrectomy; Sunitinib; Oncology; Univariate analysis; Gastroenterology; Neutrophil to lymphocyte ratio; Targeted therapy; Multivariate analysis; Cancer; Lymphocyte; Kidney","retraction":null,"screen_n_in":null,"score":{"opus":0.01334527017469415,"gpt":0.2400423819275469,"spread":0.2266971117528528,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003333398,0.0003625505,0.0007853097,0.000349386,0.0000529464,0.000008980079,0.0001545651,0.0002518828,0.00008998487],"category_scores_gemma":[0.0001275352,0.0002663012,0.0000662799,0.0007986039,0.0003925661,0.0001247452,0.00004182093,0.0003501934,0.00001231747],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005572928,"about_ca_system_score_gemma":0.001257771,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002764193,"about_ca_topic_score_gemma":0.00003721897,"domain_scores_codex":[0.9973291,0.0003512339,0.0006441796,0.0004970698,0.0004729209,0.0007055339],"domain_scores_gemma":[0.9979118,0.0001441173,0.0004709108,0.0004462315,0.0006685954,0.0003583841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02547154,0.001553004,0.9495322,0.00008816738,0.0001642539,0.0003702706,0.0009587326,0.00004465471,0.0204107,0.000002932344,0.0001543673,0.001249206],"study_design_scores_gemma":[0.02293474,0.009325909,0.9261514,0.0001545954,0.0001765838,0.000006362211,0.0002372654,0.0001382589,0.04015872,0.00001144881,0.0003969215,0.0003077638],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9947571,0.00132639,0.00002420196,0.0000792307,0.00009572449,0.002114442,0.00004887142,0.00009476824,0.001459321],"genre_scores_gemma":[0.9951711,0.00002039672,0.004043411,0.00009057805,0.00002933873,0.0001743734,0.0003075627,0.00007732237,0.00008590011],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02338075,"threshold_uncertainty_score":0.9999789,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2037096531","doi":"10.1007/s11523-012-0252-7","title":"The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":49,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; BC Cancer Agency; Princess Margaret Cancer Centre; University of Toronto; London Health Sciences Centre; University of Alberta; Queen Elizabeth II Health Sciences Centre; Sunnybrook Health Science Centre","funders":"National Cancer Institute","keywords":"Medicine; Renal cell carcinoma; Oncology; Targeted therapy; VEGF receptors; Internal medicine; Second-line therapy; Cancer; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.07733604392423403,"gpt":0.3777414729966405,"spread":0.3004054290724065,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003631328,0.000802646,0.00300275,0.000480811,0.0001905349,0.00004135615,0.0006322202,0.0006770244,0.001073458],"category_scores_gemma":[0.00177781,0.0005048224,0.0007009148,0.001065492,0.0002154967,0.0001648682,0.0001782454,0.001335607,0.000403886],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00111483,"about_ca_system_score_gemma":0.0007044455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008826692,"about_ca_topic_score_gemma":0.001804622,"domain_scores_codex":[0.9898507,0.001847274,0.004654021,0.001211993,0.00111099,0.001325],"domain_scores_gemma":[0.9909801,0.003850604,0.001720741,0.001242357,0.001293641,0.0009125918],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007323581,0.004158712,0.9573284,0.00005334341,0.000604303,0.0001123452,0.0009024803,0.00008788848,0.001221318,0.000007568217,0.00302706,0.025173],"study_design_scores_gemma":[0.02607058,0.03323248,0.9230247,0.00003346485,0.000222272,0.000008330418,0.0001682451,0.0002614625,0.003604141,0.00009105735,0.01279942,0.0004838302],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866942,0.0007377807,0.00009575522,0.005132529,0.001118932,0.005536376,0.00009421642,0.00009634795,0.0004939318],"genre_scores_gemma":[0.9853859,0.0001914958,0.006204708,0.005038609,0.0003797945,0.0007024171,0.0003185972,0.0001428231,0.001635636],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03430368,"threshold_uncertainty_score":0.9998397,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4283026383","doi":"10.1007/s11523-022-00888-9","title":"Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"National Cancer Institute; Genentech; F. Hoffmann-La Roche","keywords":"Medicine; Refractory (planetary science); Multicenter study; Phases of clinical research; Internal medicine; Oncology; Clinical trial; Randomized controlled trial","retraction":null,"screen_n_in":null,"score":{"opus":0.008484783094617332,"gpt":0.271109531333761,"spread":0.2626247482391437,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003041304,0.0002466843,0.0003832438,0.0001802256,0.0002558393,0.000009195833,0.0002230135,0.0001282495,0.0001167869],"category_scores_gemma":[0.0001664222,0.0002092585,0.00004231718,0.000253646,0.00006013284,0.000007883665,0.0004000102,0.0003350294,0.000004257279],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009085838,"about_ca_system_score_gemma":0.0002767717,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000101137,"about_ca_topic_score_gemma":0.0005519096,"domain_scores_codex":[0.9979176,0.0004137272,0.0004403475,0.000595669,0.0002103869,0.0004222733],"domain_scores_gemma":[0.9991447,0.00003871946,0.0002577488,0.0003163861,0.0001097259,0.0001327069],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.03355131,0.02647717,0.8667189,0.00009512214,0.0002162838,0.0009448751,0.00394666,0.00005321165,0.05548177,0.00001776027,0.005509992,0.006986885],"study_design_scores_gemma":[0.1872081,0.4163064,0.3335223,0.00002674535,0.0005769237,0.0002268893,0.0114979,0.0006130118,0.007605448,0.00002533105,0.04003537,0.002355564],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9977524,0.0002433422,0.00001222522,0.00003180919,0.000389837,0.001078364,0.0001084378,0.00002556382,0.0003580581],"genre_scores_gemma":[0.9981713,0.00005678477,0.0003357375,0.000216694,0.0001193673,0.0003037534,0.0003920528,0.0000398312,0.000364428],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5331967,"threshold_uncertainty_score":0.8533313,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4317209129","doi":"10.1007/s11523-022-00941-7","title":"Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Osimertinib; Lung cancer; Central nervous system; Lung; Oncology; Pathology; Cancer; Cancer research; Internal medicine; Adenocarcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.0675653515167773,"gpt":0.4399859305321071,"spread":0.3724205790153298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002055384,0.0006255333,0.002124686,0.0002589218,0.0002057989,0.00005408961,0.0001722579,0.0003553014,0.00005362489],"category_scores_gemma":[0.00002521169,0.00042087,0.0004663678,0.0003609792,0.00009817953,0.00008279788,0.00004506304,0.0005106915,0.00001548652],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002283005,"about_ca_system_score_gemma":0.004120292,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001803535,"about_ca_topic_score_gemma":0.00007246147,"domain_scores_codex":[0.9974138,0.0002373095,0.0006507976,0.0008399438,0.000207172,0.0006510506],"domain_scores_gemma":[0.9981022,0.000579492,0.0005161572,0.0003641936,0.000200798,0.0002371757],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002732237,0.0005525644,0.00002234886,0.08151145,0.003996351,0.0001729783,0.004876839,0.00002172817,0.00001308947,0.002180678,0.001291752,0.905087],"study_design_scores_gemma":[0.002201542,0.001985441,0.00011263,0.02219195,0.02644502,0.00009203528,0.01481772,0.0002118408,0.000007174259,0.0000178141,0.9313752,0.0005416219],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000116267,0.9907067,0.0001723048,0.0003664516,0.001940334,0.005584418,0.000696,0.0001650028,0.0002524772],"genre_scores_gemma":[0.001003745,0.9932168,0.0002257915,0.00006390811,0.001508656,0.00334861,0.0003128446,0.0001198196,0.0001998081],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9300835,"threshold_uncertainty_score":0.9998243,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2091875870","doi":"10.1007/s11523-013-0271-z","title":"An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; McGill University; Amgen (Canada)","funders":"Amgen","keywords":"Panitumumab; KRAS; Medicine; Internal medicine; Hazard ratio; Oncology; Post-hoc analysis; Colorectal cancer; Randomized controlled trial; Cancer; Confidence interval","retraction":null,"screen_n_in":null,"score":{"opus":0.009570761703216482,"gpt":0.3150242219557259,"spread":0.3054534602525095,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002815308,0.000319235,0.003661559,0.0002275892,0.00003986408,0.000005417109,0.00008743064,0.00008634824,0.0009090595],"category_scores_gemma":[0.0001343592,0.0001378007,0.0005727966,0.000293689,0.000216874,0.00004881467,0.00001124077,0.000122256,0.000001583664],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007260682,"about_ca_system_score_gemma":0.0001631211,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01025299,"about_ca_topic_score_gemma":0.003694863,"domain_scores_codex":[0.9973388,0.001092883,0.0006726988,0.0003245264,0.0003241998,0.000246945],"domain_scores_gemma":[0.9972518,0.001671499,0.0005572829,0.0002631272,0.0001780322,0.00007824784],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8799686,0.009560858,0.08637618,0.000009637658,0.01555625,0.000005764248,0.00133372,0.00009607254,0.0006372451,0.000001975273,0.00001289432,0.006440841],"study_design_scores_gemma":[0.7900565,0.04077827,0.1583062,0.00002672918,0.008052921,6.23751e-8,0.00006985471,0.00136419,0.001209175,0.000003775709,0.00003877571,0.0000935307],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9913372,0.0003650976,0.000003228911,0.0001236735,0.0002745977,0.007527321,0.0002082299,0.00001150691,0.0001490897],"genre_scores_gemma":[0.9975163,0.0001781133,0.00005520377,0.0001060259,0.00004283919,0.001912278,0.0001325992,0.00001984463,0.00003675594],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08991208,"threshold_uncertainty_score":0.9963378,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379509021","doi":"10.1007/s11523-023-00965-7","title":"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Insect Resistance and Genetics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":33,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta","funders":"AstraZeneca","keywords":"Medicine; Tolerability; Oncology; Internal medicine; Pharmacology; Adverse effect","retraction":null,"screen_n_in":null,"score":{"opus":0.007141951924465786,"gpt":0.3043287191005847,"spread":0.2971867671761189,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003452564,0.0001818921,0.0003260627,0.00006770404,0.0001225036,0.00001319599,0.000249017,0.0001333258,0.000007317822],"category_scores_gemma":[0.0001130048,0.0001143411,0.00004764421,0.0004006394,0.0001905471,0.00000692736,0.0001507061,0.0001919403,0.000001528695],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006290409,"about_ca_system_score_gemma":0.0002208444,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006135314,"about_ca_topic_score_gemma":0.00236733,"domain_scores_codex":[0.998477,0.0002398804,0.0004230568,0.0003680984,0.0001706375,0.00032132],"domain_scores_gemma":[0.9991884,0.00009686709,0.0001783461,0.0004152684,0.00008384055,0.00003726779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007936421,0.006577733,0.8490409,0.00005984505,0.000150528,0.00003304987,0.004203178,0.003320154,0.1040923,0.00001844778,0.0002853156,0.02428217],"study_design_scores_gemma":[0.0157697,0.006249114,0.9467859,0.00004608737,0.00002114127,0.000001860878,0.0009924195,0.0001302508,0.02639379,0.00008093577,0.003321067,0.000207719],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979107,0.0001728387,0.000005911886,0.0005769197,0.000129684,0.001034497,0.0000106651,0.00000955532,0.0001492747],"genre_scores_gemma":[0.9994047,0.00004237734,0.00005294228,0.0003003879,0.00004426927,0.00005785364,0.00002560985,0.0000228661,0.00004897271],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09774502,"threshold_uncertainty_score":0.4662696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3157804315","doi":"10.1007/s11523-021-00813-6","title":"Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies","year":2021,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":30,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sumitomo Dainippon Pharma Oncology","keywords":"Medicine; Tolerability; Adverse effect; Discontinuation; Internal medicine; Phases of clinical research; Cancer; Dosing; Oncology; Clinical trial","retraction":null,"screen_n_in":null,"score":{"opus":0.01280117383212232,"gpt":0.3102873812325547,"spread":0.2974862074004324,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00007310595,0.0001382539,0.0002840142,0.00004719582,0.0000500116,0.000008785105,0.000187197,0.0001499795,0.00002254741],"category_scores_gemma":[0.00004460802,0.0001101999,0.00001988482,0.0001976219,0.00005937784,0.000008972369,0.0001932789,0.0001244064,0.000001931405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005452123,"about_ca_system_score_gemma":0.0001266255,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005278395,"about_ca_topic_score_gemma":0.0001934698,"domain_scores_codex":[0.9988585,0.000150652,0.0002938164,0.0003562849,0.0001114318,0.0002293769],"domain_scores_gemma":[0.9993517,0.00001333944,0.0001604328,0.0002330735,0.0001850449,0.00005642283],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005372811,0.01112513,0.03183972,0.00003135003,0.0001758162,0.00009160088,0.0005926951,0.000605693,0.9249942,0.000005646942,0.0002034669,0.02496189],"study_design_scores_gemma":[0.1498056,0.03891886,0.0468003,0.0002354289,0.0001461412,0.0000119227,0.00305166,0.0001663225,0.7501227,0.00002395886,0.01004643,0.0006706641],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9981756,0.0006624949,0.00003384923,0.00004355185,0.0002011959,0.0004948695,0.00001367065,0.000005330173,0.0003693875],"genre_scores_gemma":[0.9984815,0.0001184865,0.0008929789,0.0001402164,0.00001962603,0.00003357418,0.0001571792,0.00001671736,0.0001397457],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1748714,"threshold_uncertainty_score":0.449382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2985618399","doi":"10.1007/s11523-019-00689-7","title":"High Tumor Mutation Burden and Other Immunotherapy Response Predictors in Breast Cancers: Associations and Therapeutic Opportunities","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"NOSM University; Essar Steel Algoma (Canada); Sault Area Hospital","funders":"","keywords":"Medicine; Immunotherapy; Oncology; Breast cancer; Internal medicine; Mutation; Immunology; Cancer; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.0226872329180317,"gpt":0.2912074542816495,"spread":0.2685202213636178,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005758022,0.0001492249,0.0003553175,0.0002200598,0.00005460921,0.00001609772,0.00004889587,0.0001473885,0.0005886182],"category_scores_gemma":[0.00001949361,0.0001323288,0.00003995223,0.0001608139,0.0001569664,0.00006717394,0.00001406792,0.0001677541,0.000005467014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006022614,"about_ca_system_score_gemma":0.0005274076,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002757564,"about_ca_topic_score_gemma":0.0001766306,"domain_scores_codex":[0.9988394,0.0002618575,0.0003034664,0.0002291706,0.0001320491,0.0002340717],"domain_scores_gemma":[0.9993098,0.0002708177,0.000153681,0.0001499036,0.00005450607,0.00006130624],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.07329915,0.0003102991,0.3231184,0.0001332218,0.001571647,0.0002303426,0.02330229,0.00005667184,0.3525746,0.0007511871,0.0009697962,0.2236823],"study_design_scores_gemma":[0.01269526,0.002208607,0.913357,0.00009804192,0.00007947833,0.0004003554,0.004261144,0.0003476116,0.0006262399,0.0003006734,0.06535532,0.0002703245],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9891472,0.00358201,0.000005542009,0.005955211,0.0002353166,0.0005594228,0.00009656068,0.00004881499,0.0003699498],"genre_scores_gemma":[0.9953052,0.0005394347,0.0001339003,0.002998665,0.00009751995,0.00005523787,0.00003054696,0.00002956261,0.0008098817],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5902385,"threshold_uncertainty_score":0.6444957,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2061663237","doi":"10.1007/s11523-010-0143-8","title":"Prognostic and predictive biomarkers in renal cell carcinoma","year":2010,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Renal cell carcinoma; Biomarker; Biomarker discovery; Kidney cancer; Vascular endothelial growth factor; Clear cell renal cell carcinoma; Oncology; Targeted therapy; Cancer; Pathology; Cancer research; Bioinformatics; Internal medicine; VEGF receptors; Proteomics; Biology; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.03238352251163952,"gpt":0.3148014887375521,"spread":0.2824179662259126,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003413516,0.0006287226,0.002668426,0.0006857522,0.00004806627,0.00001124527,0.0001590849,0.00131209,0.0001461473],"category_scores_gemma":[0.0001806096,0.0004751123,0.0003242225,0.0004439319,0.0002925647,0.00003865307,0.000139871,0.001394173,0.00008848382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008767198,"about_ca_system_score_gemma":0.001629903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007662957,"about_ca_topic_score_gemma":0.00005502577,"domain_scores_codex":[0.9971039,0.000399412,0.0008146793,0.0008465112,0.000236524,0.0005990082],"domain_scores_gemma":[0.9980519,0.0006048991,0.0004032744,0.0004819184,0.00008477179,0.0003732149],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003788382,0.0007691244,0.004325578,0.01230493,0.0004439303,0.005939407,0.0002437559,1.747205e-7,0.0001282803,0.00001085615,0.001123952,0.9743312],"study_design_scores_gemma":[0.002452398,0.004157866,0.008332286,0.002383964,0.00415254,0.001807739,0.00003691041,0.00002061654,0.00005756301,0.00002771155,0.9761367,0.0004336565],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.009020171,0.9784583,0.000004670914,0.00006474476,0.0003559619,0.003292629,0.00008161688,0.00005114316,0.008670705],"genre_scores_gemma":[0.007945543,0.9885826,0.001223488,0.00005303523,0.0002620796,0.0006846118,0.0007593221,0.0001051221,0.0003841729],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9750128,"threshold_uncertainty_score":0.9999844,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2076911447","doi":"10.1007/s11523-013-0299-0","title":"Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial","year":2013,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Vascular Tumors and Angiosarcomas","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Bayer HealthCare","keywords":"Medicine; Liter; Sorafenib; Placental growth factor; Internal medicine; Vascular endothelial growth factor; Endoglin; VEGF receptors; Angiosarcoma; Gastroenterology; Hepatocellular carcinoma; Pathology; Stem cell; CD34","retraction":null,"screen_n_in":null,"score":{"opus":0.04767621424879121,"gpt":0.305364035680701,"spread":0.2576878214319098,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008648988,0.0003697894,0.001400981,0.0002734873,0.000125315,0.0000147896,0.0001794042,0.0002382566,0.0004974701],"category_scores_gemma":[0.0004038116,0.0002741297,0.0001759056,0.0005205317,0.00009861073,0.0002244134,0.00008935166,0.0004833881,0.000009175965],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002818124,"about_ca_system_score_gemma":0.0002488543,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001375481,"about_ca_topic_score_gemma":0.0005078613,"domain_scores_codex":[0.9965951,0.0006059943,0.0009410302,0.0006188845,0.000683687,0.0005553469],"domain_scores_gemma":[0.9980842,0.0001933079,0.0004723217,0.0005941829,0.0004327118,0.0002232525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005616955,0.01992486,0.9572495,0.00002858441,0.0008494487,0.000358499,0.003023745,0.00002800498,0.002159995,5.665554e-7,0.0001357913,0.01062403],"study_design_scores_gemma":[0.2063836,0.02288797,0.7673975,0.0001810878,0.0004629212,0.000005500759,0.0005813159,0.001401204,0.0002568879,0.00002602995,0.00005978884,0.0003561466],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965847,0.00008324289,0.0002293534,0.0002753183,0.0001097044,0.002529476,0.00009205267,0.00006601558,0.00003017858],"genre_scores_gemma":[0.9958338,0.000001309146,0.002369463,0.0008122753,0.0001544629,0.0001019246,0.0006233247,0.00007763244,0.00002582756],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2007667,"threshold_uncertainty_score":0.9999711,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2743780916","doi":"10.1007/s11523-017-0525-2","title":"A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Sphingolipid Metabolism and Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":24,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"Ipsen","keywords":"Medicine; Internal medicine; Oncology; Cohort; Clinical endpoint; Cancer; Sorafenib; Nausea; Hepatocellular carcinoma; Response Evaluation Criteria in Solid Tumors; Clinical trial; Gastroenterology; Phases of clinical research","retraction":null,"screen_n_in":null,"score":{"opus":0.03434511081770929,"gpt":0.3299875841284284,"spread":0.2956424733107191,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004081451,0.0001870055,0.0005191876,0.0000946753,0.0001724292,0.00002016179,0.0005908302,0.0001952604,0.00002929878],"category_scores_gemma":[0.0001828492,0.0001815457,0.00003031782,0.00009512423,0.0001860637,0.00001591301,0.0006045652,0.0001522632,2.881405e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003151478,"about_ca_system_score_gemma":0.0003565034,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001334195,"about_ca_topic_score_gemma":0.0004594185,"domain_scores_codex":[0.9984612,0.0001763577,0.0004806615,0.0004502787,0.0001161699,0.0003152609],"domain_scores_gemma":[0.9986946,0.00002421031,0.0005335527,0.0005344014,0.0001107181,0.000102525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001598955,0.006037567,0.005775581,0.00003377509,0.0001019468,0.0000404663,0.002003204,0.0001359265,0.9665951,0.00002271427,0.0002451752,0.0174096],"study_design_scores_gemma":[0.06059996,0.01643127,0.001555169,0.00003731065,0.0001582917,0.00001215888,0.001307848,0.002156506,0.9120677,0.00004372466,0.005268689,0.0003613847],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9962522,0.001852707,0.0002441456,0.00003267999,0.0002260724,0.0009725576,0.00003750415,0.000003633166,0.0003784578],"genre_scores_gemma":[0.9978653,0.00006615471,0.00167132,0.00004605933,0.0001144309,0.00006704825,0.00003998907,0.00001964889,0.0001100438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.059001,"threshold_uncertainty_score":0.7403218,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4310595717","doi":"10.1007/s11523-022-00931-9","title":"Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovaderm (Canada)","funders":"Mirati Therapeutics","keywords":"Medicine; Nausea; Pharmacokinetics; Vomiting; Adverse effect; Internal medicine; Gastroenterology; Cancer; Response Evaluation Criteria in Solid Tumors; Capsule; Pharmacology; Chemotherapy; Progressive disease","retraction":null,"screen_n_in":null,"score":{"opus":0.01739782352627714,"gpt":0.3924252135381065,"spread":0.3750273900118293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000208725,0.0001420056,0.0004246721,0.0001416337,0.000105649,0.00000405135,0.00004272607,0.00003245275,0.000135277],"category_scores_gemma":[0.00001875203,0.0001156409,0.00001528462,0.000195775,0.00005223292,0.00005781875,0.00007340485,0.0001591881,1.811752e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002824197,"about_ca_system_score_gemma":0.0004033885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005488279,"about_ca_topic_score_gemma":0.0003706998,"domain_scores_codex":[0.9988573,0.0001369488,0.0003051084,0.0003113261,0.0001875461,0.0002017799],"domain_scores_gemma":[0.9994079,0.00005688754,0.0002087801,0.0001429384,0.00008762399,0.00009579462],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002602349,0.007667087,0.9345664,0.00008993834,0.0001890496,0.00003906879,0.01974802,0.0005206783,0.005130203,0.00000374161,0.00003405384,0.02940939],"study_design_scores_gemma":[0.1924106,0.1402149,0.6292018,0.0001603555,0.001777186,0.00001323491,0.02817238,0.004297727,0.00275914,0.00003471213,0.0004550222,0.0005028989],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9971561,0.0004170589,0.000007213415,0.00004650976,0.00008750438,0.00186828,0.0001082408,0.0000147111,0.0002943382],"genre_scores_gemma":[0.9970857,0.000004298767,0.001969744,0.0002143389,0.00002744507,0.0005475041,0.00005633682,0.00002825602,0.0000663926],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3053646,"threshold_uncertainty_score":0.47157,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3092483376","doi":"10.1007/s11523-020-00748-4","title":"Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":19,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"Amgen","keywords":"Medicine; Rituximab; Internal medicine; Follicular lymphoma; Clinical endpoint; Confidence interval; CD20; Randomized controlled trial; Lymphoma; Gastroenterology; Ofatumumab; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.03036682753850691,"gpt":0.2829847304425309,"spread":0.252617902904024,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004286056,0.0001877664,0.0007537552,0.0000486585,0.00004836886,0.000004591113,0.0002166471,0.0002687605,0.00005664999],"category_scores_gemma":[0.0004973854,0.0001034875,0.0000257634,0.0003527777,0.00043889,0.00003480081,0.00009050237,0.0003018732,0.000006288954],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004937149,"about_ca_system_score_gemma":0.0001234807,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003876417,"about_ca_topic_score_gemma":0.0004933921,"domain_scores_codex":[0.9978067,0.000772702,0.0006003626,0.0004761829,0.00005823035,0.0002858358],"domain_scores_gemma":[0.9986205,0.0007723157,0.0002500519,0.0002514511,0.00007142119,0.0000343104],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8510591,0.00411478,0.09266313,0.00002267952,0.0004159058,0.00002648342,0.002145738,0.00002605081,0.005775806,0.0002029564,0.001297026,0.04225034],"study_design_scores_gemma":[0.30204,0.008689594,0.6605241,0.00006969572,0.0001323241,0.000002373758,0.0001871238,0.00004029103,0.005186556,0.00003889569,0.02284697,0.0002420307],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939764,0.0008601223,0.00003723909,0.003570403,0.00009072766,0.00101713,0.0001429238,0.00001562898,0.0002894677],"genre_scores_gemma":[0.9974738,0.00003070742,0.001803433,0.0004311252,0.0000279576,0.00001602905,0.0001914204,0.000009799661,0.00001576356],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.567861,"threshold_uncertainty_score":0.4220097,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2962334030","doi":"10.1007/s11523-019-00652-6","title":"Acquired EGFR L718V Mutation as the Mechanism for Osimertinib Resistance in a T790M-Negative Non-Small-Cell Lung Cancer Patient","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Power Generation","funders":"","keywords":"Osimertinib; T790M; Medicine; Lung cancer; Oncology; Epidermal growth factor receptor; Adenocarcinoma; Internal medicine; Resistance mutation; Cancer; Cancer research; Gefitinib; Erlotinib; Gene; Biology; Genetics; Polymerase chain reaction","retraction":null,"screen_n_in":null,"score":{"opus":0.01104115390947608,"gpt":0.329290657629553,"spread":0.3182495037200769,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001242116,0.0001771637,0.0003473251,0.00009978176,0.0001045753,0.000009926953,0.0000919244,0.0001538064,0.0003145136],"category_scores_gemma":[0.00008661456,0.0001264162,0.00008854656,0.0002441171,0.00004303606,0.0000642972,0.00002592602,0.0001220775,0.00004845765],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009373471,"about_ca_system_score_gemma":0.000866871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007800438,"about_ca_topic_score_gemma":0.001522685,"domain_scores_codex":[0.9987284,0.0000806543,0.0003457728,0.0003522198,0.0001489716,0.0003439724],"domain_scores_gemma":[0.9988894,0.0003163084,0.0002293485,0.0002396038,0.0002472783,0.00007805484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"qualitative","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02871427,0.009482682,0.04687369,0.003530667,0.005708647,0.001066076,0.450745,0.003300224,0.2826968,0.05856307,0.05412516,0.05519373],"study_design_scores_gemma":[0.1482311,0.02469845,0.1022137,0.002330136,0.007409668,0.0001111829,0.04416842,0.03743218,0.4459077,0.06124487,0.1232478,0.00300474],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9705588,0.001162164,0.0006918348,0.006900124,0.0008060782,0.005061537,0.00008569136,0.00004878507,0.01468497],"genre_scores_gemma":[0.9859747,0.00006553991,0.003589954,0.003285062,0.00007345714,0.002147926,0.0001044904,0.00003489807,0.004723936],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4065766,"threshold_uncertainty_score":0.5155102,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387930721","doi":"10.1007/s11523-023-00997-z","title":"A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Cetuximab; Medicine; Internal medicine; Head and neck squamous-cell carcinoma; Oncology; Head and neck cancer; Phases of clinical research; Cancer; Clinical trial; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03311622994514312,"gpt":0.3371139118074929,"spread":0.3039976818623498,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001915665,0.000154033,0.0007094927,0.000366742,0.00003096041,0.000002538118,0.00004326696,0.00004397662,0.00001559348],"category_scores_gemma":[0.00006619061,0.0001016773,0.00001269507,0.0008034289,0.0000670223,0.00004838817,0.00003881572,0.0001862287,0.000002940901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001767995,"about_ca_system_score_gemma":0.0002179419,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004922863,"about_ca_topic_score_gemma":0.005634248,"domain_scores_codex":[0.9987243,0.0001463085,0.000355476,0.0002804807,0.0002193628,0.0002740899],"domain_scores_gemma":[0.9993911,0.000157142,0.0001210912,0.0001407901,0.0001183733,0.00007148743],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01988211,0.04284288,0.9055656,0.00036249,0.00005243822,0.0005748317,0.01677986,0.00001266483,0.00009135796,0.000005931099,0.0004171417,0.01341271],"study_design_scores_gemma":[0.1480133,0.1170461,0.7306224,0.00007167181,0.00009802722,0.000003991529,0.003513092,0.0002923994,0.0000873509,0.000008303023,0.0001350472,0.0001082857],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997743,0.0002064776,0.000002017551,0.0002159383,0.000065248,0.001510952,0.00001424813,0.00002388625,0.0002182709],"genre_scores_gemma":[0.9994711,0.00001629534,0.0001823509,0.0000676765,0.000007536144,0.0001411761,0.00005026092,0.00001813813,0.00004544305],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1749432,"threshold_uncertainty_score":0.4146281,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3095962378","doi":"10.1007/s11523-020-00770-6","title":"Everolimus in Advanced Breast Cancer: A Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; Western University","funders":"","keywords":"Medicine; Everolimus; Exemestane; Oncology; Internal medicine; Hazard ratio; Breast cancer; Odds ratio; Metastatic breast cancer; Meta-analysis; Confidence interval; Cancer; Aromatase","retraction":null,"screen_n_in":null,"score":{"opus":0.06320616612665578,"gpt":0.4072449643067012,"spread":0.3440387981800455,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004822548,0.0008699363,0.026422,0.0006029755,0.00004179889,0.000009506435,0.0003094721,0.0004577535,0.001331766],"category_scores_gemma":[0.0001931611,0.0005859674,0.002451215,0.002529964,0.0001360389,0.00009381954,0.0001345892,0.000918377,0.00006076755],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001175154,"about_ca_system_score_gemma":0.0009924308,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008153608,"about_ca_topic_score_gemma":0.0001585376,"domain_scores_codex":[0.9952826,0.0009261746,0.001910742,0.001019613,0.0003176937,0.0005431447],"domain_scores_gemma":[0.9969066,0.0004336522,0.001358437,0.0007986491,0.0001704945,0.000332102],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.00004633565,0.00006628202,0.000001478492,0.753356,0.1657603,0.0002747533,0.00005521551,0.000002554681,2.910621e-7,0.00001550055,0.00003729704,0.08038396],"study_design_scores_gemma":[0.0004765571,0.0001154536,0.000004428259,0.03100643,0.6831998,0.0008124434,0.00001532859,0.000003463827,5.950908e-8,0.00001330574,0.2840327,0.0003200739],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[1.730505e-7,0.9902333,0.00003752101,0.003163558,0.00006206219,0.005734152,0.0005672884,0.0001009275,0.0001010171],"genre_scores_gemma":[0.00000979028,0.9894756,0.0008036016,0.003991348,0.00006633114,0.005046284,0.0001532957,0.0001056682,0.0003480738],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.7223496,"threshold_uncertainty_score":0.9996592,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1973375841","doi":"10.1007/s11523-009-0120-2","title":"Nuclear imaging of molecular processes in cancer","year":2009,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Thomas Hospital","funders":"University College London Hospitals NHS Foundation Trust; National Institute for Health and Care Research; Cancer Research UK","keywords":"Molecular imaging; Medicine; Positron emission tomography; Nuclear medicine; Nuclear imaging; Pet imaging; Medical physics; Cancer; Internal medicine; In vivo; Biology; Biotechnology","retraction":null,"screen_n_in":null,"score":{"opus":0.04336537521571856,"gpt":0.424973262258337,"spread":0.3816078870426185,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001591019,0.0001975992,0.001509222,0.0002386435,0.00001414937,0.000002748536,0.0001869641,0.0002419099,0.0002796359],"category_scores_gemma":[0.0001950544,0.0001586122,0.0001460954,0.0005755629,0.0001217679,0.00001730183,0.00004639971,0.0005157337,0.00001415588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002267389,"about_ca_system_score_gemma":0.001190092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007945729,"about_ca_topic_score_gemma":0.000005136896,"domain_scores_codex":[0.9987114,0.00006384004,0.0005705076,0.0002884012,0.0001332651,0.0002325906],"domain_scores_gemma":[0.9991448,0.00007724819,0.0002911825,0.000281647,0.0001034311,0.0001016868],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000005372384,0.0002447613,0.00001019384,0.01014058,0.0000285526,0.0001187442,0.00003091454,1.08041e-7,0.0001006642,0.0002517707,0.00554525,0.9835231],"study_design_scores_gemma":[0.0002110935,0.00009600501,0.000004348927,0.008372205,0.0004318119,0.0000841502,0.000005561235,0.00001997493,0.00004271664,0.000187884,0.9904227,0.0001215967],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002542497,0.9944199,0.0000892594,0.001901342,0.0000321036,0.0008149568,0.00001298079,0.00009449638,0.002609514],"genre_scores_gemma":[0.0001305146,0.9908784,0.007780978,0.0007607522,0.00006608477,0.0002082568,0.00006995605,0.00003925215,0.00006577723],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9848774,"threshold_uncertainty_score":0.6468018,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3172387625","doi":"10.1007/s11523-021-00822-5","title":"Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis","year":2021,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Ethics in Clinical Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Narodowe Centrum Nauki","keywords":"Medicine; Meta-analysis; Oncology; Targeted therapy; Clinical trial; Internal medicine; Pediatric oncology; Intensive care medicine; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.7192358579784843,"gpt":0.652057374042999,"spread":0.06717848393548531,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaresearch","research_integrity"],"category_scores_codex":[0.06966418,0.001000444,0.04507556,0.002486033,0.0001359854,0.00003016742,0.0006678529,0.00286666,0.001068631],"category_scores_gemma":[0.1082302,0.0005934852,0.005638743,0.00567712,0.0002475843,0.00006465684,0.0003041904,0.00493134,0.00001654461],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001232114,"about_ca_system_score_gemma":0.005586476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001544638,"about_ca_topic_score_gemma":0.001988608,"domain_scores_codex":[0.9757965,0.0124251,0.007847525,0.001815776,0.001117939,0.0009971767],"domain_scores_gemma":[0.8752439,0.1156428,0.00552165,0.001812398,0.001203604,0.0005756214],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.0006458588,0.003661616,0.00005693635,0.8090748,0.1368291,0.0009767603,0.000224341,0.000002925738,2.112713e-7,0.0001962414,0.0004501028,0.04788115],"study_design_scores_gemma":[0.009814103,0.009024778,0.000008443047,0.04989371,0.8039145,0.00008210688,0.00004738326,0.00003205257,4.117935e-7,0.0006611295,0.125954,0.0005673115],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007831729,0.976823,0.00007499807,0.001335987,0.0001188071,0.0209414,0.000470515,0.00003815291,0.0001188665],"genre_scores_gemma":[0.00003162779,0.97993,0.003337583,0.001465977,0.0001821399,0.01308208,0.0009807365,0.0001251064,0.0008646896],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.759181,"threshold_uncertainty_score":0.9998446,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4393260725","doi":"10.1007/s11523-024-01046-z","title":"Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Pfizer","keywords":"Palbociclib; Medicine; Breast cancer; Randomized controlled trial; Population; Metastatic breast cancer; Clinical trial; Oncology; Internal medicine; Cochrane Library; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.01904652755948039,"gpt":0.3726052928173543,"spread":0.3535587652578739,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003870018,0.001032511,0.008891428,0.0005581289,0.00004234086,0.00001492411,0.0003493895,0.0003358122,0.000520232],"category_scores_gemma":[0.0001211988,0.0006279317,0.0005419663,0.001605426,0.0001770909,0.0001357526,0.0001097475,0.001278875,0.0003295558],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002492673,"about_ca_system_score_gemma":0.001973815,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002166043,"about_ca_topic_score_gemma":0.00005646733,"domain_scores_codex":[0.9952031,0.0005565082,0.001889941,0.001013769,0.0005370835,0.000799606],"domain_scores_gemma":[0.9971908,0.0003018939,0.0010857,0.0008764153,0.0002812398,0.0002639932],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.00007882003,0.0002834196,0.00002151238,0.6856462,0.0008133145,0.0003062794,0.00006518031,7.202185e-7,5.20153e-8,0.00001461457,0.0003061198,0.3124638],"study_design_scores_gemma":[0.00218852,0.0004254971,0.00004995349,0.7680913,0.01537965,0.0007696668,0.00002589642,0.000001671816,4.099325e-8,0.00003263458,0.2125267,0.0005084893],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000008219356,0.9875009,0.00001821902,0.0004022144,0.0004722731,0.01075529,0.0005040405,0.0001788336,0.0001600358],"genre_scores_gemma":[0.00001525919,0.9896883,0.000740845,0.001275657,0.0001207187,0.006838881,0.0004861807,0.000277651,0.0005565155],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3119553,"threshold_uncertainty_score":0.9996172,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2957412264","doi":"10.1007/s11523-019-00654-4","title":"A Monoclonal Antibody Against β1 Integrin Inhibits Proliferation and Increases Survival in an Orthotopic Model of High-Grade Meningioma","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Meningioma and schwannoma management","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; Hamilton General Hospital","funders":"Meningioma Mommas","keywords":"Medicine; Integrin; Meningioma; Monoclonal antibody; Cancer research; Protein kinase B; Laminin; In vivo; In vitro; Pathology; Antibody; Cell; Phosphorylation; Immunology; Internal medicine; Biology; Receptor; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02769570325496929,"gpt":0.3088989663630577,"spread":0.2812032631080885,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004230546,0.0001766282,0.0005745712,0.0003508297,0.00002932546,0.00001022026,0.00007983264,0.0001744361,0.00004818764],"category_scores_gemma":[0.00006415919,0.0001575103,0.00004342943,0.0002139113,0.00006391673,0.0001530188,0.00008410951,0.0002105968,0.000006989073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0000998585,"about_ca_system_score_gemma":0.0001937278,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002275789,"about_ca_topic_score_gemma":0.0001424025,"domain_scores_codex":[0.9985039,0.0001811881,0.0004678186,0.0003637248,0.000213325,0.0002700766],"domain_scores_gemma":[0.9993291,0.00006938561,0.0001513075,0.000232885,0.00008879614,0.0001284474],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.001194114,0.001058974,0.4726882,0.0002342437,0.0001022118,0.0003782167,0.001332121,0.001499716,0.511194,0.007895906,0.00004198846,0.002380356],"study_design_scores_gemma":[0.01665554,0.00714556,0.5486929,0.0003183334,0.0002200716,0.0002345566,0.001275994,0.3816196,0.04087618,0.0019869,0.0002734357,0.0007009068],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970092,0.0001035221,0.0002647461,0.0002960821,0.0001084741,0.0008328237,0.00001037261,0.00004291317,0.00133185],"genre_scores_gemma":[0.9944972,0.00001084904,0.004836129,0.0001054924,0.00005885776,0.00003843803,0.0002607869,0.00001696548,0.0001752282],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4703178,"threshold_uncertainty_score":0.6423085,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4366351020","doi":"10.1007/s11523-023-00957-7","title":"Place in Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: A Targeted Literature Review","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"EVERSANA (Canada)","funders":"Pfizer","keywords":"Medicine; Oncology; Metastatic breast cancer; Breast cancer; Internal medicine; Palbociclib; Targeted therapy; Chemotherapy; Cyclin-dependent kinase 4; Cancer; Clinical trial; Cell cycle; Cyclin-dependent kinase 2","retraction":null,"screen_n_in":null,"score":{"opus":0.03738858245496208,"gpt":0.3918227242008502,"spread":0.3544341417458882,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.001006491,0.0009881755,0.006519103,0.001370503,0.00003254988,0.000009233269,0.0004903257,0.001250966,0.0004330504],"category_scores_gemma":[0.0001875708,0.0007876815,0.0006964157,0.003689762,0.0002145214,0.0001286385,0.0001581488,0.002314442,0.00005961083],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002348232,"about_ca_system_score_gemma":0.002833559,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00038843,"about_ca_topic_score_gemma":0.0005301843,"domain_scores_codex":[0.9940795,0.0009501642,0.002441122,0.001097409,0.0005239445,0.0009078669],"domain_scores_gemma":[0.9967598,0.0005124359,0.001348197,0.0008600546,0.0002740484,0.0002454765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006893022,0.000534559,0.0001656713,0.06671678,0.0003871562,0.001690596,0.0003693348,0.00001049555,0.00007091243,0.00001712544,0.001089234,0.9282588],"study_design_scores_gemma":[0.003495185,0.0003348967,0.0002325275,0.2431091,0.0003089466,0.0006242805,0.00004319963,0.000003160072,0.00001620328,0.00006594577,0.7512399,0.0005266579],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001120028,0.9918593,0.000001563288,0.001838486,0.0008648305,0.004259733,0.0007966116,0.0001506002,0.0001168592],"genre_scores_gemma":[0.00004174427,0.9950386,0.0002384123,0.0009730776,0.0005224151,0.001858156,0.0006970182,0.0002459978,0.0003846113],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9277322,"threshold_uncertainty_score":0.9999872,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281722441","doi":"10.1007/s11523-022-00884-z","title":"A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study","year":2022,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Boehringer Ingelheim","keywords":"Medicine; Afatinib; Internal medicine; Oncology; Response Evaluation Criteria in Solid Tumors; Neratinib; Cancer; Epidermal growth factor receptor; Breast cancer; Clinical trial; Erlotinib; Phases of clinical research; Trastuzumab","retraction":null,"screen_n_in":null,"score":{"opus":0.06037269198487216,"gpt":0.3976504848924063,"spread":0.3372777929075341,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002510458,0.0001435063,0.0004946864,0.0002228886,0.0001372912,0.000008243514,0.0004163508,0.00005549452,0.0006613979],"category_scores_gemma":[0.0002563814,0.00008481225,0.00005398884,0.0007316454,0.0002081671,0.00003737838,0.0001551904,0.000875572,0.000006332511],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006614012,"about_ca_system_score_gemma":0.001222755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008565953,"about_ca_topic_score_gemma":0.001022864,"domain_scores_codex":[0.996179,0.001899615,0.0005330911,0.0003248538,0.0006845536,0.0003788231],"domain_scores_gemma":[0.9985084,0.0005567675,0.00017357,0.0006203688,0.00008485038,0.00005604618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1988132,0.08735282,0.6199746,0.00008722726,0.0003573895,0.0004243444,0.07346888,0.001014582,0.0024229,0.0000929484,0.008171339,0.007819805],"study_design_scores_gemma":[0.2078932,0.05190501,0.7054503,0.00001771944,0.00008770936,0.000004907346,0.02772318,0.0005094949,0.00007277742,0.00006678484,0.006107938,0.0001609554],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9906309,0.00007477202,0.000003218423,0.001651134,0.0001986003,0.006330674,0.00006467061,0.00001350108,0.001032507],"genre_scores_gemma":[0.9966329,0.000004027884,0.0000513598,0.0006831027,0.00006991305,0.0024321,0.00003854327,0.00002430003,0.00006375035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08547573,"threshold_uncertainty_score":0.7241843,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2789468111","doi":"10.1007/s11523-018-0559-0","title":"Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naïve Patients: a Systematic Review and Network Meta-Analysis","year":2018,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Ipsen; Canadian Centre for Applied Research in Cancer Control","keywords":"Cabozantinib; Medicine; Sunitinib; Internal medicine; Sorafenib; Oncology; Hazard ratio; Renal cell carcinoma; Meta-analysis; Bevacizumab; Temsirolimus; Progression-free survival; Subgroup analysis; Confidence interval; Overall survival; Hepatocellular carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","retraction":null,"screen_n_in":null,"score":{"opus":0.1109176175775262,"gpt":0.3834524545767004,"spread":0.2725348369991741,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":[],"category_scores_codex":[0.0006304622,0.001030165,0.01990034,0.0007520819,0.00005067696,0.000008653652,0.0002723555,0.00028099,0.0001218391],"category_scores_gemma":[0.0001019576,0.0005274687,0.002932166,0.00213786,0.000244144,0.00004321312,0.00004319188,0.0002291624,0.00001093464],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001955843,"about_ca_system_score_gemma":0.0007891983,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001970364,"about_ca_topic_score_gemma":0.0009594042,"domain_scores_codex":[0.9920517,0.002986619,0.003028026,0.0008383878,0.0005093332,0.0005858881],"domain_scores_gemma":[0.9939665,0.001882243,0.002389771,0.001267064,0.0003358678,0.0001585097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.002168489,0.004189379,0.0009010123,0.8429807,0.1339708,0.0007869894,0.003517839,0.00005984657,1.758232e-7,0.00002424165,0.0001836984,0.01121679],"study_design_scores_gemma":[0.007827555,0.04039405,0.0001600012,0.01615049,0.902218,0.00002828465,0.0004979063,0.000004226001,0.000009032134,0.000003540688,0.03233243,0.0003745051],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00533972,0.9819739,0.000001477434,0.00002194607,0.0001021203,0.01159677,0.0005085053,0.00001053468,0.0004450076],"genre_scores_gemma":[0.01377785,0.9814775,0.0008016214,0.00003506158,0.00003433058,0.002598417,0.00116028,0.00005894893,0.00005599214],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8268302,"threshold_uncertainty_score":0.9997177,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2735753765","doi":"10.1007/s11523-017-0516-3","title":"A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer","year":2017,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Inflammatory Biomarkers in Disease Prognosis","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Jewish General Hospital; Hôpital Notre-Dame; McGill University; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Hazard ratio; Prostate cancer; Testosterone (patch); Internal medicine; White blood cell; Neutrophil to lymphocyte ratio; Absolute neutrophil count; Prospective cohort study; Proportional hazards model; Gastroenterology; Urology; Complete blood count; Cancer; Lymphocyte; Confidence interval; Oncology; Toxicity; Neutropenia","retraction":null,"screen_n_in":null,"score":{"opus":0.0143465471483212,"gpt":0.2977672131610162,"spread":0.2834206660126951,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002530647,0.0001446266,0.0005455494,0.0001392544,0.00004737133,0.000006572608,0.0001112818,0.0001814866,0.0001369549],"category_scores_gemma":[0.0002542301,0.0001343027,0.00004511801,0.00005836434,0.0003810861,0.00009869371,0.00009919907,0.0001450105,0.000001579054],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001464448,"about_ca_system_score_gemma":0.0004591978,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004447861,"about_ca_topic_score_gemma":0.0001674613,"domain_scores_codex":[0.9987823,0.0001280634,0.0004100564,0.0002415611,0.0002250844,0.0002129347],"domain_scores_gemma":[0.998708,0.0000984945,0.0005321855,0.0002839086,0.0002783347,0.00009910159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.005077966,0.0009824306,0.9367784,0.0005019187,0.0001800681,0.00007919293,0.001639515,0.000003053477,0.05367095,0.00004068822,0.00008556389,0.0009602609],"study_design_scores_gemma":[0.01517893,0.002603187,0.9438586,0.0002076471,0.0002629943,0.000007350842,0.0001602091,0.0005532386,0.03658556,0.0002439959,0.0002177995,0.0001205455],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957349,0.0005064902,0.000007843185,0.0004186864,0.0001823678,0.0009705643,0.0001673135,0.00001785107,0.001993951],"genre_scores_gemma":[0.9991483,0.0001655204,0.0003135138,0.00006623076,0.00002007364,0.0001112191,0.00002564544,0.00001798455,0.0001315178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01708539,"threshold_uncertainty_score":0.5476704,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4403977769","doi":"10.1007/s11523-024-01102-8","title":"Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; AstraZeneca","keywords":"Medicine; Olaparib; Maximum tolerated dose; Open label; Refractory (planetary science); Oncology; Solid tumor; Internal medicine; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04736721586451495,"gpt":0.3932493215087382,"spread":0.3458821056442233,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005576173,0.0002565929,0.0006612406,0.0005271815,0.00006859771,0.00005446629,0.0001443086,0.0002406728,0.0001743209],"category_scores_gemma":[0.00005644666,0.0002015466,0.00001319528,0.0006173435,0.0001631349,0.0005795851,0.00005225877,0.000600329,0.00001148036],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008688731,"about_ca_system_score_gemma":0.0008163056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002043127,"about_ca_topic_score_gemma":0.0005107737,"domain_scores_codex":[0.9978244,0.0002975633,0.0005493316,0.0006087988,0.0003353266,0.0003845443],"domain_scores_gemma":[0.999105,0.0001414644,0.0001762677,0.0002794457,0.0001209927,0.0001767838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7615173,0.0410376,0.03966582,0.0003788258,0.0002897566,0.001781845,0.01003888,0.00006630912,0.03827224,0.001055211,0.002696331,0.1031998],"study_design_scores_gemma":[0.7865131,0.1359274,0.06188533,0.001371819,0.0001101367,0.00005252402,0.0004562224,0.001760978,0.002260846,0.0004626954,0.00861908,0.0005798321],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953721,0.0003081219,0.0000453358,0.0005598791,0.0003601155,0.002388487,0.00002284123,0.00009839472,0.0008447329],"genre_scores_gemma":[0.9974567,0.00004865121,0.0009209593,0.0005876909,0.0001168783,0.0002942797,0.0004119539,0.00005870688,0.0001042109],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.10262,"threshold_uncertainty_score":0.8218831,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2989651221","doi":"10.1007/s11523-019-00685-x","title":"Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Oncology; Castration; Internal medicine; Prostate; Cancer; Hormone","retraction":null,"screen_n_in":null,"score":{"opus":0.06205601479162649,"gpt":0.388488184776486,"spread":0.3264321699848595,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005015924,0.0002179891,0.0006052415,0.00007916406,0.0001266457,0.00002556759,0.00007653965,0.00006285586,0.000046137],"category_scores_gemma":[0.0002220359,0.0001313501,0.0000717116,0.0001535101,0.00004098086,0.00008615873,0.00003898333,0.0001719741,0.00001842058],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000852591,"about_ca_system_score_gemma":0.0007449758,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01450601,"about_ca_topic_score_gemma":0.01285866,"domain_scores_codex":[0.9982631,0.0002046525,0.0004299157,0.0004489498,0.0002165721,0.0004368584],"domain_scores_gemma":[0.9973498,0.002000702,0.0001628834,0.0002444239,0.0001585844,0.00008362655],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.03132623,0.003513669,0.8071624,0.00009367232,0.002830668,0.0009144856,0.0677935,0.005845375,0.03299592,0.000217745,0.0003691978,0.04693712],"study_design_scores_gemma":[0.09006305,0.01464112,0.835722,0.0002614523,0.001165181,0.00001838083,0.02267468,0.02334828,0.009048719,0.0008717361,0.001712996,0.00047237],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9905395,0.0006829297,0.00004324613,0.002779356,0.0003255981,0.004759546,0.0004095999,0.00004144045,0.0004187845],"genre_scores_gemma":[0.9956095,0.0001531729,0.00229343,0.0001239412,0.0001430985,0.0005167823,0.0005222168,0.00002743088,0.0006104147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05873682,"threshold_uncertainty_score":0.9920565,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387032788","doi":"10.1007/s11523-023-01000-5","title":"A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer","year":2023,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"AstraZeneca","keywords":"Medicine; Observational study; Gemcitabine; Cochrane Library; Internal medicine; MEDLINE; Chemotherapy; Cancer; Biliary tract cancer; Oncology; Intensive care medicine; Meta-analysis","retraction":null,"screen_n_in":null,"score":{"opus":0.08894734557234671,"gpt":0.4349304150010871,"spread":0.3459830694287404,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003896098,0.0006377137,0.0074644,0.000661762,0.00003698922,0.000009146161,0.0001339962,0.0002111055,0.0001805396],"category_scores_gemma":[0.0002452648,0.0003581536,0.0005281483,0.001224798,0.00006460693,0.00006125225,0.00007968666,0.0004151441,0.000008853263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001119007,"about_ca_system_score_gemma":0.001195356,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00179759,"about_ca_topic_score_gemma":0.01186122,"domain_scores_codex":[0.9966377,0.0005322728,0.00151236,0.0006309166,0.0002456723,0.0004410833],"domain_scores_gemma":[0.9973014,0.001165324,0.0007632425,0.0005033652,0.0001261164,0.0001405566],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0001161555,0.0003289392,0.00378654,0.6490956,0.001753317,0.001848176,0.0004348892,1.54002e-7,6.999631e-7,0.000007878759,0.0009064229,0.3417212],"study_design_scores_gemma":[0.003103031,0.001559127,0.007728439,0.6165014,0.007304468,0.0002383455,0.0001144191,0.000002270426,0.00000158317,0.000006325857,0.363048,0.0003926268],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001563959,0.9929994,5.488014e-7,0.0003958788,0.0003378542,0.004779141,0.0009310538,0.00006028094,0.0003393943],"genre_scores_gemma":[0.00007172084,0.9920999,0.0001614193,0.000222141,0.00007987121,0.00327703,0.0004581373,0.00008571103,0.003544012],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.3621416,"threshold_uncertainty_score":0.999887,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406352769","doi":"10.1007/s11523-024-01126-0","title":"Buparlisib and Paclitaxel in Patients with Head and Neck Squamous Cell Carcinoma: Immunogenomic Biomarkers of Efficacy from the BERIL-1 Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Paclitaxel; Head and neck; Head and neck squamous-cell carcinoma; Basal cell; Internal medicine; Oncology; Carcinoma; Head and neck cancer; Chemotherapy; Radiation therapy; Surgery","retraction":null,"screen_n_in":null,"score":{"opus":0.0106481787802106,"gpt":0.2746714922898457,"spread":0.264023313509635,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001570443,0.0001544273,0.0005920678,0.0000906956,0.00007782515,0.000004497389,0.00007034637,0.00008249222,0.00001446657],"category_scores_gemma":[0.00007079614,0.00009910976,0.00002450934,0.0002138558,0.0002170883,0.00002308172,0.0001084985,0.0001663193,0.000001106103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001159177,"about_ca_system_score_gemma":0.0001797732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003406701,"about_ca_topic_score_gemma":0.001343907,"domain_scores_codex":[0.9989538,0.0001380908,0.0003075646,0.0002868928,0.00009512223,0.0002185517],"domain_scores_gemma":[0.9991219,0.0004424869,0.00008588569,0.0002374275,0.00006246729,0.00004985118],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003512874,0.001181136,0.9863645,0.00003702402,0.0001243156,0.00001821673,0.003746551,5.942315e-7,0.0009951292,0.000003406947,0.0004384978,0.003577773],"study_design_scores_gemma":[0.0214771,0.005228142,0.9697378,0.00003731852,0.0001788015,8.293126e-7,0.002373351,0.000007194043,0.0002203153,0.00001318496,0.0006424159,0.00008359611],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9911042,0.006243971,9.117491e-7,0.0004993839,0.0001145651,0.001017844,0.00003522217,0.00001163141,0.0009723046],"genre_scores_gemma":[0.9994565,0.00004039798,0.0001389499,0.0002458659,0.00001789775,0.00003136251,0.00001848567,0.00001117563,0.00003935587],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01796423,"threshold_uncertainty_score":0.5149935,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2900971116","doi":"10.1007/s11523-018-0603-0","title":"Targeting the Proteasome in Refractory Pediatric Leukemia Cells: Characterization of Effective Cytotoxicity of Carfilzomib","year":2018,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Children's Hospital; University of Calgary","funders":"Alberta Children's Hospital Foundation","keywords":"Carfilzomib; Medicine; Cytotoxicity; Refractory (planetary science); Cancer research; Proteasome inhibitor; Leukemia; Oncology; Immunology; Multiple myeloma; In vitro; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.00839942384022,"gpt":0.2487751456260181,"spread":0.2403757217857981,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006953678,0.0001462424,0.000279147,0.00009340866,0.00006090138,0.000003345285,0.0002356564,0.0002968498,0.0000513274],"category_scores_gemma":[0.0002738014,0.0001171854,0.00006848555,0.0002553256,0.0002224136,0.000007129916,0.0001366527,0.0001878301,0.000008152476],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008471053,"about_ca_system_score_gemma":0.0002957996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007138577,"about_ca_topic_score_gemma":0.00002006392,"domain_scores_codex":[0.998492,0.0004482754,0.0003972962,0.000276033,0.0001115871,0.0002748003],"domain_scores_gemma":[0.9990155,0.00006352796,0.0004093368,0.0002503418,0.000219749,0.00004154742],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0003021455,0.00009799603,0.004173458,0.00007188752,0.000019174,0.000002152786,0.0004668368,0.000009800739,0.9939621,0.00004301946,0.00008583004,0.0007655646],"study_design_scores_gemma":[0.0006475,0.001510999,0.02197407,0.000008961338,0.00001705346,0.000002480148,0.00008267196,0.00008002936,0.9726841,0.00004855813,0.002823246,0.0001203452],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997443,0.0002220514,0.0003460007,0.00002553745,0.0001747599,0.0009762832,0.00004415638,0.000009395314,0.0007588125],"genre_scores_gemma":[0.998625,0.0001133444,0.0002993174,0.00008833554,0.0005355328,0.0001443659,0.00009669676,0.00001905195,0.00007838731],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02127805,"threshold_uncertainty_score":0.4778681,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4410569892","doi":"10.1007/s11523-025-01146-4","title":"Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation","year":2025,"lang":"en","type":"review","venue":"Targeted Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"AstraZeneca","keywords":"Medicine; Olaparib; Abiraterone; Prostate cancer; Oncology; PARP inhibitor; Internal medicine; Docetaxel; Cancer; BRCA mutation; Ovarian cancer; Poly ADP ribose polymerase; Androgen receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.04601313563003731,"gpt":0.3846335911876247,"spread":0.3386204555575874,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001430023,0.0003290381,0.00140745,0.0002591354,0.00006861582,0.0000121293,0.00005420106,0.0001308659,0.000052124],"category_scores_gemma":[0.00001761806,0.0001631495,0.00007263575,0.0004293298,0.0001536745,0.0000575117,0.000003907043,0.0001156938,4.181811e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001001201,"about_ca_system_score_gemma":0.001889789,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002638254,"about_ca_topic_score_gemma":0.002004161,"domain_scores_codex":[0.998441,0.0001891405,0.0006282583,0.0003501008,0.0001779676,0.0002135127],"domain_scores_gemma":[0.9981377,0.0006953949,0.0006344875,0.0002073859,0.0002801986,0.00004483882],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01257394,0.00160972,0.0002907618,0.00761174,0.001273204,0.00002577778,0.001646684,0.00005229401,0.00001220758,0.00008230214,0.00007844187,0.9747429],"study_design_scores_gemma":[0.08790901,0.05859505,0.004569127,0.01455463,0.006805617,0.00003849417,0.0003842794,0.0002192822,0.0001932469,0.0001775547,0.8258963,0.0006574315],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00774233,0.9787567,0.0004829609,0.000416933,0.0001343226,0.01171355,0.0007022199,0.00002457629,0.00002641558],"genre_scores_gemma":[0.001882721,0.986869,0.001859237,0.0001107762,0.00002712964,0.00795483,0.0008690401,0.00004726596,0.0003800399],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9740855,"threshold_uncertainty_score":0.6653043,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2913025776","doi":"10.1007/s11523-018-00618-0","title":"Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520","year":2019,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cell Adhesion Molecules Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Juravinski Cancer Centre","funders":"Boehringer Ingelheim","keywords":"Medicine; Pharmacokinetics; Focal adhesion; Crossover; Crossover study; Pharmacology; Kinase; Pathology; Phosphorylation; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.08393497142852478,"gpt":0.4287001567482334,"spread":0.3447651853197086,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004021076,0.0002050777,0.0008414396,0.00008511315,0.0001722105,0.00001437582,0.0003446358,0.000146121,0.0001104063],"category_scores_gemma":[0.003429103,0.00008478809,0.0001235885,0.0003169482,0.0005095095,0.00004905269,0.0006669981,0.0004664452,0.00001092492],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001238637,"about_ca_system_score_gemma":0.0001876954,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002506024,"about_ca_topic_score_gemma":0.000008408129,"domain_scores_codex":[0.9967704,0.001425969,0.000577712,0.000288141,0.0006580018,0.0002798026],"domain_scores_gemma":[0.9912645,0.007436762,0.0004100059,0.0004776704,0.0003540003,0.00005704012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1613615,0.000244131,0.0002379854,0.0002076613,0.000275421,0.00000168583,0.0005777587,0.0001100139,0.8335797,0.0004865672,0.0004551027,0.002462444],"study_design_scores_gemma":[0.2047946,0.02494056,0.0004995674,0.0002208339,0.0003906052,0.0000122133,0.0001730117,0.01302542,0.7552974,0.0001039165,0.0004435721,0.00009823853],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898922,0.001208496,0.00002103116,0.002557049,0.0003056309,0.005255928,0.00001150065,0.00001027783,0.0007379178],"genre_scores_gemma":[0.9986463,0.0001248456,0.0001712774,0.0005088429,0.00009007696,0.0001604066,0.000006010616,0.00002654434,0.0002657156],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07828232,"threshold_uncertainty_score":0.4105205,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2516587078","doi":"10.1007/s11523-016-0448-3","title":"Effect of Targeting Clusterin Using OGX-011 on Antitumor Activity of Temsirolimus in a Human Renal Cell Carcinoma Model","year":2016,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Clusterin in disease pathology","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Temsirolimus; Clusterin; Medicine; Renal cell carcinoma; Pharmacology; Cancer research; Apoptosis; Downregulation and upregulation; PI3K/AKT/mTOR pathway; Internal medicine; Biology; Discovery and development of mTOR inhibitors","retraction":null,"screen_n_in":null,"score":{"opus":0.02798368675883016,"gpt":0.3393615595728084,"spread":0.3113778728139782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008223639,0.0002741965,0.001100048,0.0004505115,0.00004222788,0.000001575565,0.000169751,0.0003033098,0.0001213814],"category_scores_gemma":[0.000337177,0.0002060159,0.0001706973,0.000214579,0.0003121912,0.00006020355,0.0002030184,0.0002777958,0.000006984588],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004404714,"about_ca_system_score_gemma":0.0002720095,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002056109,"about_ca_topic_score_gemma":0.00002758523,"domain_scores_codex":[0.9975312,0.0006446142,0.0006408741,0.000468595,0.0002223831,0.0004923197],"domain_scores_gemma":[0.9983289,0.0005206128,0.0004575002,0.0004563354,0.00009146457,0.0001451574],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004732091,0.0006098195,0.02939914,0.000516171,0.00002052398,0.0003434869,0.0002147506,0.0009653123,0.9612254,0.00002062233,0.00007795917,0.001874703],"study_design_scores_gemma":[0.01057312,0.008299536,0.03617638,0.0002649036,0.0001654221,0.00009099389,0.00001991753,0.02182384,0.9222398,0.00007474575,0.00003111053,0.000240243],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963496,0.00007518766,0.0007426434,0.00009984439,0.0001629408,0.0007135805,0.00004974467,0.00003453808,0.001771935],"genre_scores_gemma":[0.9982816,0.000004420235,0.00136602,0.00006099145,0.00009542602,0.00003238678,0.00001015787,0.00004578215,0.0001032089],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03898563,"threshold_uncertainty_score":0.8401083,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386346584","doi":"10.1007/s11523-023-00995-1","title":"Comparative Effectiveness of Lurbinectedin for the Treatment of Relapsed Small Cell Lung Cancer in the Post-Platinum Setting: A Real-World Canadian Synthetic Control Arm Analysis","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"University of Manitoba; CancerCare Manitoba; University of Calgary","funders":"Jazz Pharmaceuticals Canada","keywords":"Medicine; Hazard ratio; Confidence interval; Proportional hazards model; Population; Internal medicine; Oncology; Chemotherapy; Surgery; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.02779027094144856,"gpt":0.3760701408180536,"spread":0.3482798698766051,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001099495,0.0001863786,0.001070746,0.0006916682,0.0001221091,0.000004342102,0.0001821364,0.00008502207,0.00006589325],"category_scores_gemma":[0.0002583653,0.0001032293,0.0002398188,0.001937882,0.0002236198,0.0000142031,0.00001646254,0.0001737029,0.000001864463],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001435067,"about_ca_system_score_gemma":0.00138766,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2569824,"about_ca_topic_score_gemma":0.6812501,"domain_scores_codex":[0.9979017,0.0007349748,0.000386029,0.0002837557,0.0002047485,0.0004888371],"domain_scores_gemma":[0.990859,0.008127633,0.0002010178,0.0003273454,0.0003915486,0.00009347211],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01405725,0.002265108,0.8199118,0.001869409,0.02232457,0.0002933442,0.06476423,0.02530938,0.04107756,0.0004812824,0.004253585,0.003392423],"study_design_scores_gemma":[0.01029083,0.00494912,0.9336466,0.000144474,0.005787261,0.000002221441,0.00355699,0.03204209,0.00747028,0.00004725725,0.001902945,0.0001598848],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9831791,0.002376086,0.00003676093,0.00611405,0.0001608039,0.005363888,0.0007055335,0.00002982397,0.002033987],"genre_scores_gemma":[0.9970306,0.0003268592,0.00004617685,0.00009604316,0.00005442079,0.002066548,0.00009442216,0.00001583462,0.0002691565],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4242676,"threshold_uncertainty_score":0.7479654,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4386387581","doi":"10.1007/s11523-023-00987-1","title":"Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial","year":2023,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"National Cancer Institute; Ono Pharmaceutical; Memorial Sloan-Kettering Cancer Center; Bristol-Myers Squibb","keywords":"Nivolumab; Medicine; Ipilimumab; Renal cell carcinoma; Placebo; Nephrectomy; Internal medicine; Adjuvant; Oncology; Adjuvant therapy; Kidney cancer; Clinical trial; Cancer; Surgery; Immunotherapy; Kidney; Pathology; Alternative medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.1294819005494149,"gpt":0.4061370170159111,"spread":0.2766551164664962,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004184816,0.0005768373,0.002927763,0.001290189,0.0001960681,0.0000268179,0.00036195,0.0006690525,0.0007114696],"category_scores_gemma":[0.0007241075,0.0004735655,0.0009997744,0.001278095,0.0009073537,0.00011531,0.0002787065,0.0008029089,0.0002468076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001558914,"about_ca_system_score_gemma":0.002579333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006114048,"about_ca_topic_score_gemma":0.0001675277,"domain_scores_codex":[0.9934477,0.001416497,0.00155507,0.001023574,0.001071327,0.001485827],"domain_scores_gemma":[0.9928762,0.0043649,0.0004780614,0.0009360838,0.0007643797,0.0005803716],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9729884,0.001540491,0.00002651248,0.0005006477,0.0006436632,0.001694228,0.00112127,0.00003920258,0.006114898,0.00006995045,0.01369233,0.001568364],"study_design_scores_gemma":[0.9187047,0.01941757,0.00001818584,0.0000928947,0.001304079,0.0000456092,0.0004491053,0.002938949,0.03391765,0.0002157193,0.02254076,0.0003547865],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9731466,0.00268675,0.0002210593,0.0007919429,0.001633249,0.01521273,0.0001736573,0.0002549028,0.005879077],"genre_scores_gemma":[0.9804446,0.0002141002,0.00257718,0.00009116631,0.0009080499,0.008176319,0.001042654,0.0001539837,0.006391986],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05428374,"threshold_uncertainty_score":0.9997716,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2021963511","doi":"10.1007/s11523-008-0093-6","title":"Mechanisms of resistance to EGFR tyrosine kinase inhibitors: implications for patient selection and drug combination strategies","year":2008,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Parks and Wilderness Society","funders":"","keywords":"Medicine; Cetuximab; Epidermal growth factor receptor; EGFR inhibitors; Tyrosine kinase; Lung cancer; Cancer; Colorectal cancer; Cancer research; Drug resistance; Gefitinib; Erlotinib; Signal transduction; Targeted therapy; Receptor tyrosine kinase; Bioinformatics; Oncology; Internal medicine; Receptor; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.01352074422015656,"gpt":0.3217577086328896,"spread":0.3082369644127331,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004814715,0.00007659663,0.0001775559,0.0001043794,0.0001316231,0.000003629713,0.00001981764,0.00005443317,0.00001011594],"category_scores_gemma":[0.00004058709,0.00006988258,0.00002853598,0.0001894058,0.00003668686,0.00006556516,0.000009765346,0.00004068105,0.000001407194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000234067,"about_ca_system_score_gemma":0.000289006,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006621027,"about_ca_topic_score_gemma":0.0001962911,"domain_scores_codex":[0.9994351,0.00002268467,0.0002024694,0.0001635237,0.0000592758,0.0001168909],"domain_scores_gemma":[0.9994079,0.00005917133,0.00009747549,0.00008657415,0.000278791,0.00007009793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001583875,0.002939438,0.005350699,0.0003300832,0.0003597753,0.00001254537,0.01194995,0.0002099972,0.7052166,0.2102399,0.04089665,0.02091043],"study_design_scores_gemma":[0.01995478,0.01847108,0.3182119,0.0002918692,0.001257013,0.0001988467,0.007284769,0.00035186,0.4471731,0.1000685,0.08598457,0.0007517035],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9667816,0.000513002,0.02021013,0.009035636,0.0001835168,0.001659043,0.00009145134,0.00006713155,0.001458515],"genre_scores_gemma":[0.9845944,0.00003174028,0.01431981,0.0002442595,0.00002534013,0.000332282,0.0001213199,0.00001089007,0.0003199632],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3128611,"threshold_uncertainty_score":0.2849728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3111069302","doi":"10.1007/s11523-020-00778-y","title":"Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Group for Research in Decision Analysis","funders":"Merck Sharp and Dohme","keywords":"Medicine; Pembrolizumab; Nivolumab; Internal medicine; Population; Cohort; Retrospective cohort study; Oncology; Cancer; Immunotherapy; Environmental health","retraction":null,"screen_n_in":null,"score":{"opus":0.03138123723126232,"gpt":0.292119504055217,"spread":0.2607382668239546,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010182,0.0002063803,0.0004800756,0.0001506545,0.0000631076,0.00001281063,0.00007636839,0.0001329781,0.00003263498],"category_scores_gemma":[0.00003827471,0.0001196029,0.00002458963,0.0007367753,0.0001275655,0.00005125324,0.00002771471,0.0001406912,0.000008106094],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006896252,"about_ca_system_score_gemma":0.0003334798,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002310034,"about_ca_topic_score_gemma":0.01500088,"domain_scores_codex":[0.9983649,0.0003163219,0.0002926987,0.0004103487,0.0002569513,0.0003587431],"domain_scores_gemma":[0.9992856,0.0001595345,0.0001103765,0.0002019955,0.0000645199,0.0001780129],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006129529,0.001181097,0.9732995,0.00003753287,0.00003981905,0.0004123898,0.001297625,0.000008855739,0.000004693057,0.000258572,0.000518264,0.01681209],"study_design_scores_gemma":[0.02585494,0.007923138,0.9596117,0.00007524346,0.00007719097,0.00002449942,0.0002561159,0.0002947015,0.00004932332,0.000007860282,0.005705141,0.000120192],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864709,0.0001162123,0.000002571755,0.01035549,0.00001069169,0.0009708356,0.00001374127,0.00003463409,0.002024893],"genre_scores_gemma":[0.9967493,0.00005615654,0.0001865795,0.002535426,0.00003999819,0.0001250501,0.0002359443,0.00002376112,0.00004780125],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01972541,"threshold_uncertainty_score":0.8370842,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4392654691","doi":"10.1007/s11523-024-01034-3","title":"Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC","year":2024,"lang":"en","type":"letter","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University Health Network","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Lung cancer; Oncology; Internal medicine; Placebo; Epidermal growth factor receptor; Stage (stratigraphy); Cancer; Pathology; Erlotinib; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.05860293502871478,"gpt":0.4132749408906006,"spread":0.3546720058618859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0005387332,0.0003630721,0.001126922,0.001236289,0.00005745647,0.00001570152,0.0002085488,0.001097535,0.0005824367],"category_scores_gemma":[0.0001986261,0.0002696759,0.000133311,0.001228218,0.0004351359,0.0000548556,0.0001051985,0.003560665,0.0001135405],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001434703,"about_ca_system_score_gemma":0.003365556,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002608804,"about_ca_topic_score_gemma":0.0007513887,"domain_scores_codex":[0.9963957,0.0006267311,0.0006664403,0.0007205689,0.0007770609,0.0008134873],"domain_scores_gemma":[0.9977887,0.0007966255,0.0001852177,0.0005498812,0.0005576245,0.0001220018],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001743595,0.00036791,0.001322074,0.0008183856,0.001215244,0.01432609,0.0009776804,0.000009627731,0.001088318,0.00007232265,0.9772144,0.0008443289],"study_design_scores_gemma":[0.006653113,0.004587006,0.00476775,0.001547935,0.0008042743,0.0001389611,0.0002101715,0.00005631667,0.000421778,0.0006128612,0.979879,0.0003208191],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.04261807,0.005958894,0.000009655209,0.8336922,0.001616607,0.003273336,0.0005731751,0.0003063295,0.1119517],"genre_scores_gemma":[0.2660829,0.001876582,0.004290188,0.493734,0.01044913,0.002637031,0.0369955,0.001313388,0.1826213],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3399582,"threshold_uncertainty_score":0.9999756,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4411055081","doi":"10.1007/s11523-025-01153-5","title":"Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Newfoundland and Labrador; AstraZeneca","keywords":"Medicine; Osimertinib; Concordance; Acquired resistance; Biopsy; Oncology; Circulating tumor DNA; Pathology; Internal medicine; Cancer; Adenocarcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.006775695507202522,"gpt":0.2802244547159031,"spread":0.2734487592087006,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002553032,0.0001649472,0.0003270762,0.0001199513,0.00005251673,0.000009102005,0.0001549413,0.0001169444,0.000003937951],"category_scores_gemma":[0.0005027063,0.0001723131,0.00002189724,0.0003063567,0.0001152782,0.000004304229,0.0001262525,0.000109783,0.000001061144],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009245567,"about_ca_system_score_gemma":0.0003915494,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008877285,"about_ca_topic_score_gemma":0.0003981485,"domain_scores_codex":[0.9987602,0.00009910459,0.0003483954,0.0004304558,0.00007422941,0.0002876447],"domain_scores_gemma":[0.9991544,0.0001914418,0.0001480262,0.0003105534,0.0001166523,0.00007892838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.004398358,0.00004802141,0.0201065,0.00004261107,0.00002802525,0.00005790396,0.0001237525,0.0004026652,0.9695062,0.0002494724,0.0001226579,0.004913826],"study_design_scores_gemma":[0.003227339,0.001239384,0.2166205,0.0002362228,0.00002619632,0.00001850674,0.0003230688,0.00001449388,0.7550409,0.0003050796,0.02264674,0.0003015773],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951422,0.002411462,0.0006718727,0.0005493937,0.0002566234,0.0003555561,0.00003389982,0.00001008142,0.0005688774],"genre_scores_gemma":[0.9824583,0.00009439106,0.01678023,0.000232525,0.00008200469,0.0000741878,0.00001425664,0.00001967594,0.000244434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2144653,"threshold_uncertainty_score":0.7026725,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404024879","doi":"10.1007/s11523-024-01111-7","title":"Durvalumab Following Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Differences in Survival Based on Age and Post-Progression Systemic Therapy","year":2024,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital; University of British Columbia; University of Victoria","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Chemoradiotherapy; Stage (stratigraphy); Oncology; Systemic therapy; Lung cancer; Internal medicine; Cancer; Pathology; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.02161984062590372,"gpt":0.3270869353708606,"spread":0.3054670947449569,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006022924,0.0002937964,0.0007763236,0.000286318,0.0000939692,0.00004321594,0.0001217829,0.0002888963,0.0001400035],"category_scores_gemma":[0.00001509655,0.0002201629,0.0002184535,0.0002893019,0.00008034671,0.00005040903,0.00001350869,0.0002724668,0.000001083408],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005685231,"about_ca_system_score_gemma":0.0006530057,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006351239,"about_ca_topic_score_gemma":0.0002259544,"domain_scores_codex":[0.9982865,0.0001413867,0.0004143009,0.0005255578,0.0002034474,0.0004287338],"domain_scores_gemma":[0.9991047,0.0004288523,0.000103072,0.0002203996,0.00004514397,0.00009779623],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.02539829,0.0006223256,0.04223529,0.001956106,0.0005432815,0.0009859779,0.00395238,0.0000282805,0.8025211,0.00002758736,0.00063131,0.1210981],"study_design_scores_gemma":[0.2215115,0.04134141,0.3151552,0.01392116,0.0009545745,0.0001330002,0.00619163,0.2254925,0.1216783,0.00007286698,0.05003971,0.003508197],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628816,0.03142665,0.0003710811,0.00137591,0.001546074,0.001882516,0.00005681872,0.0001121807,0.0003472235],"genre_scores_gemma":[0.9939567,0.002981942,0.0005177154,0.0009953172,0.0002198359,0.0004857345,0.0000734706,0.00006124566,0.0007079839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6808428,"threshold_uncertainty_score":0.8977982,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4416937861","doi":"10.1007/s11523-025-01187-9","title":"Tebentafusp in Metastatic Uveal Melanoma: A Meta-analysis","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Standard of care; MEDLINE; Patient care; Neoplasm staging; Overall survival","retraction":null,"screen_n_in":null,"score":{"opus":0.04936342569924775,"gpt":0.3741072122374792,"spread":0.3247437865382315,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004125738,0.0002029475,0.001750209,0.0008795787,0.00005696973,0.00000469243,0.0001030335,0.0002051479,0.002405626],"category_scores_gemma":[0.0001200561,0.0001532664,0.0008048965,0.001460791,0.0001090295,0.00004278287,0.00005590522,0.0002963568,0.0001575532],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003592131,"about_ca_system_score_gemma":0.0004243642,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003076789,"about_ca_topic_score_gemma":0.001725555,"domain_scores_codex":[0.9982826,0.0003812108,0.000458078,0.0003977641,0.0001290356,0.0003512956],"domain_scores_gemma":[0.999081,0.0002986765,0.000105695,0.0003556271,0.00006356278,0.00009549503],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.001176681,0.005049452,0.2650328,0.00008491095,0.7067606,0.005790392,0.0005147441,0.0001632029,0.000736518,0.00618783,0.003568446,0.00493444],"study_design_scores_gemma":[0.009205165,0.001730405,0.1311111,0.000004471968,0.8125602,0.00008652634,0.0003108048,0.0005517324,0.001159557,0.0035811,0.03945138,0.0002475416],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8382761,0.0176615,0.001624828,0.02378532,0.0006191925,0.002248502,0.000075262,0.0002269731,0.1154823],"genre_scores_gemma":[0.9861504,0.00002766822,0.005158182,0.002543711,0.00001417422,0.0002017892,0.0001378931,0.00001019093,0.005755975],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1478743,"threshold_uncertainty_score":0.9985063,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4417274131","doi":"10.1007/s11523-025-01186-w","title":"Idasanutlin in Combination with Chemotherapy or Venetoclax in Pediatric and Young Adult Patients with Relapsed/Refractory Solid Tumors (iMATRIX Idasa): Results of a Phase I/II, Multicenter, Multi-arm Study","year":2025,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada); Alberta Children's Hospital","funders":"Genentech; Roche","keywords":"Young adult; Chemotherapy; Venetoclax; Phases of clinical research; Solid tumor","retraction":null,"screen_n_in":null,"score":{"opus":0.01157666888915094,"gpt":0.3287658524750596,"spread":0.3171891835859086,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005355217,0.0003052426,0.0008735686,0.001050753,0.00008961003,0.000007834848,0.0001798019,0.0002363351,0.00001752439],"category_scores_gemma":[0.0007756669,0.0002202213,0.00003061811,0.001281986,0.0001938563,0.0001324124,0.0001386871,0.0005826995,0.00000189836],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002132975,"about_ca_system_score_gemma":0.001947718,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00115927,"about_ca_topic_score_gemma":0.002786492,"domain_scores_codex":[0.9971836,0.000309399,0.0009264746,0.0006027874,0.0004670836,0.0005107166],"domain_scores_gemma":[0.9981808,0.0004354761,0.0003858723,0.0003590282,0.0004959209,0.0001429061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1035213,0.03291063,0.8484727,0.0003067711,0.000158865,0.0005939678,0.009294133,0.00006993258,0.000546548,0.000005515997,0.0002517446,0.003867873],"study_design_scores_gemma":[0.3472647,0.04186456,0.5942246,0.0002820959,0.0001394769,0.00001251634,0.001763882,0.01370574,0.000469015,0.000005235371,0.00004814007,0.0002199739],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9958847,0.00009805208,0.0001121367,0.000195588,0.00009821633,0.003412462,0.00003064836,0.00004134157,0.0001268369],"genre_scores_gemma":[0.9975013,0.0001208904,0.001613607,0.0001660392,0.00002871308,0.0001930058,0.0000944995,0.00004201461,0.0002399873],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2542481,"threshold_uncertainty_score":0.8980365,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4238104384","doi":"10.1007/s11523-020-00772-4","title":"Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product","year":2020,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Western University","funders":"","keywords":"Medicine; Paragraph; Rituximab; Follicular lymphoma; Lymphoma; Internal medicine; Medical physics; Oncology; World Wide Web","retraction":null,"screen_n_in":null,"score":{"opus":0.02245929450660679,"gpt":0.2756866625027647,"spread":0.2532273679961579,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001514222,0.0001604081,0.0006363153,0.00005791898,0.000031904,0.000005220001,0.00006859991,0.00007141687,0.000011908],"category_scores_gemma":[0.000424709,0.00009109738,0.00001967308,0.0003880786,0.00007146352,0.00003401222,0.00003793375,0.00009614293,0.000006045025],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002639568,"about_ca_system_score_gemma":0.0002278655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002205532,"about_ca_topic_score_gemma":0.001774959,"domain_scores_codex":[0.9985637,0.0001646543,0.0004624398,0.0004167795,0.0002058462,0.0001865673],"domain_scores_gemma":[0.9989492,0.0004495764,0.0001865859,0.0002258651,0.00008792079,0.0001008861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.4457036,0.005711347,0.5099275,0.00001207203,0.0001362133,0.00006068707,0.002881208,0.0001415218,0.00008669858,0.000009677274,0.001821606,0.0335079],"study_design_scores_gemma":[0.2465579,0.01078377,0.7387747,0.0001247957,0.00009699731,0.000002158811,0.0001271325,0.0001489241,0.0006846313,0.000001534495,0.002618265,0.0000791909],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9940767,0.0001767323,0.000008038482,0.003047646,0.0001443352,0.002158313,0.00004780018,0.0000175036,0.0003228803],"genre_scores_gemma":[0.998553,0.00002157785,0.0006097002,0.0003642437,0.00006924078,0.00008569688,0.0002755422,0.00001179537,0.000009141576],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2288473,"threshold_uncertainty_score":0.3714843,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1980810683","doi":"10.1007/s11523-007-0042-9","title":"Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study","year":2007,"lang":"en","type":"article","venue":"Targeted Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ste. Anne's Hospital","funders":"National Cancer Institute; World Health Organization","keywords":"Docetaxel; Medicine; Gefitinib; Internal medicine; Lung cancer; Chemotherapy; Oncology; Combination therapy; Adverse effect; Rash; Cancer; Epidermal growth factor receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.0137413535267044,"gpt":0.3733654310320024,"spread":0.359624077505298,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005291632,0.0002342474,0.0008643102,0.0002229526,0.0001295597,0.000006746282,0.00006536022,0.00009821825,0.0001727428],"category_scores_gemma":[0.0000222326,0.0001516705,0.00006875884,0.0003079906,0.00007640886,0.00007661715,0.00001113805,0.0001795068,9.733042e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004611395,"about_ca_system_score_gemma":0.0007000841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002129518,"about_ca_topic_score_gemma":0.00277845,"domain_scores_codex":[0.9986129,0.00007200992,0.0004309144,0.0003626129,0.0001411918,0.0003803176],"domain_scores_gemma":[0.9988188,0.0003398481,0.0002648326,0.000185219,0.0002751122,0.0001161475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8425724,0.0346819,0.01902081,0.0002301801,0.002012602,0.0004741406,0.02389068,0.0004887555,0.01055907,0.0001569265,0.0003802418,0.0655323],"study_design_scores_gemma":[0.9486617,0.03443628,0.003401035,0.00007282327,0.000794697,0.00001786468,0.001883077,0.001067884,0.006155689,0.00004239933,0.003240324,0.0002261739],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9807699,0.001248539,0.005572032,0.0006347677,0.000147837,0.009187584,0.00003958636,0.00005602288,0.002343761],"genre_scores_gemma":[0.9885989,0.0001178749,0.006316091,0.0006186607,0.00007964971,0.002652295,0.000212395,0.00004307291,0.001361058],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1060894,"threshold_uncertainty_score":0.6184942,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}